Developer docs
API playgroundTry for free, no card

Search company profiles

Vir Biotechnology

Full company profile

uuid0000zft

Namestring
Vir Biotechnology
Legal namestring
Vir Biotechnology, Inc.
Websiteurl
vir.bio
Company typeenum
Public
Founded yearint
2016
Descriptiontext

Vir Biotechnology is a clinical-stage biopharmaceutical company headquartered in San Francisco, California, with antibody discovery operations through its wholly-owned subsidiary Humabs BioMed SA in Bellinzona, Switzerland. Founded in 2016 and listed on NASDAQ under the ticker VIR, the company develops therapeutics that engage the immune system to treat and prevent serious infectious diseases and cancer, supported by two core technology platforms: a proprietary antibody and T-cell engager discovery platform that combines natural antibody repertoires from recovered patients with the proprietary dAIsY AI engine for candidate optimization, and the PRO-XTEN protease-releasable masking platform (licensed from Amunix Pharmaceuticals, a Sanofi company) that enables tumor-selective activation of potent T-cell engagers.

The company's most advanced clinical program is the tobevibart + elebsiran combination for chronic hepatitis delta virus (HDV) infection, currently in the Phase 3 SOLSTICE/ECLIPSE registrational trial with FDA Breakthrough Therapy, FDA Fast Track, EMA PRIME, and EU Orphan Drug designations. The oncology pipeline consists of three PRO-XTEN-masked T-cell engagers — VIR-5500 (PSMA, partnered globally with Astellas Pharma), VIR-5818 (HER2), and VIR-5525 (EGFR) — all in Phase 1 development. Earlier-stage programs include the CMV-vector-based HIV T-cell vaccine VIR-1388, next-generation COVID-19 antibody VIR-7229, influenza antibody VIR-2981, and HPV therapeutic vaccine VIR-1949. Vir has a historical track record of FDA-approved antibodies including ansuvimab-zykl for Ebola (2020) and sotrovimab for COVID-19 (with GSK).

Vir's business model is partnership-driven: it monetizes assets through licensing and collaboration agreements rather than direct sales, generating revenue from upfront payments, milestones, royalties, and non-dilutive government and foundation grants (BARDA, Bill & Melinda Gates Foundation). Recent major transactions include the global Astellas collaboration for VIR-5500 (up to $1.7B total value, $335M upfront/near-term plus $75M equity) and the Norgine exclusive license for hepatitis delta in Europe, Australia, and New Zealand (€55M upfront plus up to €495M in milestones). The company retains US commercial rights for hepatitis delta and is building internal commercial capabilities for direct US launch, while the Brii Biosciences partnership covers Greater China. As of Q1 2026, Vir held $809.3M in cash and investments, reported a $125.7M quarterly net loss, and was led by CEO Marianne De Backer (appointed April 2023).

Short descriptiontext

Vir Biotechnology is a clinical-stage biopharmaceutical company that develops antibody-based immunotherapies for infectious diseases and cancer, with a Phase 3 hepatitis delta program and three oncology T-cell engager candidates. The San Francisco-based, NASDAQ-listed firm (VIR) partners with Astellas, Norgine, and others to commercialize its pipeline.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
251–500
akta.pro rankint
HeadquartersSan Francisco, United States
HQ citystring
San Francisco
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
monoclonal antibody therapeutics, infectious disease treatments, oncology biologics, T-cell engager therapies, clinical-stage biopharmaceuticals
Industry3 codes
PRIMARYHLAAADAA
mRNA Therapeutics (vaccines, protein replacement, immuno-oncology)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAAEAD
Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAAABAL
Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
NAICS code1 code
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Biopharmaceuticals
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model4 records
1Collaboration and License Revenue
TypeLicensing Royalties
Description

Upfront payments, milestone payments, and equity investments from strategic partners. Includes $335M in upfront and near-term payments from Astellas (plus $75M equity investment) for the VIR-5500 license, and €55M upfront from Norgine for the chronic hepatitis delta license in Europe. Q4 2025 recognized $64.1M in revenue from the Norgine transaction.

2Government and Foundation Grants
TypeProfessional Services
Description

Non-dilutive funding from agencies and foundations for specific R&D programs. Includes BARDA funding for COVID-19 and pandemic preparedness, and Bill & Melinda Gates Foundation grants for HIV vaccine and HIV cure research.

3Equity Financing (Public Offerings)
TypeOne Time License
Description

Capital raised through public stock offerings to fund clinical development. Recently completed a $172.5M public offering of 20,294,117 shares at $8.50 per share.

4Royalty and Milestone Payments (Future)
TypeLicensing Royalties
Description

Future revenue from licensed products including tiered royalties and development/commercial milestones. The Astellas deal includes up to $1.7B in total potential value including milestones and royalties on VIR-5500 sales in the US.

Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
Pricing details3 tiers
1Public equity offering — February 2026
ModelOtherBilling cadencePay-as-you-go
Notes

$172.5M raised via public offering of 20,294,117 shares at $8.50 per share.

2Norgine licensing transaction (chronic hepatitis delta, Europe)
ModelOtherBilling cadenceMulti-year contract
Notes

€55M upfront payment plus potential milestones and royalties; recognized $64.1M in Q4 2025 revenue.

3Astellas strategic collaboration (VIR-5500, US)
ModelOtherBilling cadenceMulti-year contract
Notes

$335M upfront and near-term payments plus $75M equity investment; total potential deal value up to $1.7B including development, regulatory, and commercial milestones plus royalties.

GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Vir Biotechnology is a clinical-stage biopharmaceutical company that develops antibody-based immunotherapies for infectious diseases and cancer. Its pipeline includes monoclonal antibodies (e.g., tobevibart), siRNA therapeutics (e.g., elebsiran), and PRO-XTEN-masked T-cell engagers, with its lead program (tobevibart + elebsiran) in Phase 3 for chronic hepatitis delta. The company commercializes through strategic partnerships with Astellas (prostate cancer), Norgine (hepatitis delta in Europe), GSK (sotrovimab for COVID-19), and Alnylam (siRNA), supported by its proprietary dAIsY AI antibody discovery engine and the licensed PRO-XTEN masking platform.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Phase 3 SOLSTICE trial readout for tobevibart + elebsiran combination in chronic hepatitis delta expected to support regulatory approval and commercial launch in US and Europe
+2 more records
Product overview1 text field

Vir Biotechnology operates a platform-plus-program portfolio built on two core technology platforms (the Antibody and T-cell Engager Discovery and Engineering Platform and the PRO-XTEN® protease-releasable masking platform) that together support a clinical pipeline spanning infectious diseases and oncology. The clinical portfolio includes the lead registrational hepatitis delta program (tobevibart + elebsiran), three PRO-XTEN-masked T-cell engagers (VIR-5818 targeting HER2, VIR-5500 targeting PSMA co-developed with Astellas, and VIR-5525 targeting EGFR), marketed antibodies (sotrovimab for COVID-19, ansuvimab-zykl for Ebola), and earlier-stage candidates in HIV (VIR-1388), HPV (VIR-1949), influenza (VIR-2981), and next-generation COVID-19 (VIR-7229), supported by the proprietary dAIsY AI engine and collaborations with partners including Astellas, Norgine, Brii Biosciences, and the Bill & Melinda Gates Foundation.

Product and service10 records
1Tobevibart + Elebsiran combination
CategoryClinical-stage combination therapy (chronic hepatitis delta)
Description

Investigational combination of a neutralizing monoclonal antibody (tobevibart, incorporating Xencor's Xtend Fc technology) and an siRNA (elebsiran) for the treatment of chronic hepatitis delta virus (HDV) infection, currently in Phase 3 development for patients with chronic HDV, a severe form of viral hepatitis with no approved therapies in the US.

2VIR-5500
CategoryClinical-stage oncology asset (PSMA-targeted PRO-XTEN masked T-cell engager)
Description

Investigational PSMA-targeting PRO-XTEN dual-masked T-cell engager for metastatic castration-resistant prostate cancer (mCRPC), evaluated alone and in combination with androgen receptor pathway inhibitors; partnered globally with Astellas Pharma in a deal worth up to $1.7 billion.

3VIR-5818
CategoryClinical-stage oncology asset (HER2-targeted PRO-XTEN masked T-cell engager)
Description

Investigational HER2-targeting PRO-XTEN dual-masked T-cell engager being evaluated alone or in combination with pembrolizumab for HER2-expressing solid tumors; currently in Phase 1 clinical development.

4VIR-5525
CategoryClinical-stage oncology asset (EGFR-targeted PRO-XTEN masked T-cell engager)
Description

Investigational EGFR-targeting PRO-XTEN dual-masked T-cell engager being evaluated alone or in combination with pembrolizumab for EGFR-expressing solid tumors; currently in Phase 1 clinical development.

5Sotrovimab
CategoryMarketed monoclonal antibody (COVID-19)
Description

Investigational monoclonal antibody treatment for COVID-19, identified by Vir's antibody platform and engineered for immune engagement; delivered during the pandemic in partnership with GlaxoSmithKline.

6Ansuvimab-zykl
CategoryMarketed monoclonal antibody (Ebola)
Description

FDA-approved (2020) monoclonal antibody treatment for Ebola virus disease (Zaire ebolavirus), derived from Vir Biotechnology's antibody discovery platform.

7VIR-7229
CategoryInvestigational next-generation COVID-19 antibody
Description

Next-generation COVID-19 monoclonal antibody candidate optimized via AI engineering for increased potency, breadth, and resistance to viral escape; developed with BARDA support for high-risk populations including immunocompromised individuals.

8VIR-2981
CategoryInvestigational monoclonal antibody (influenza)
Description

Investigational monoclonal antibody candidate with in vitro potent activity against all major strains of influenza A and B viruses, targeting high-risk populations including the elderly and immunocompromised.

9VIR-1388
CategoryInvestigational HIV T-cell vaccine
Description

Investigational HIV T-cell vaccine based on a human cytomegalovirus (HCMV) vector platform designed to elicit CD8+ T-cell immune responses against HIV, supported by the Bill & Melinda Gates Foundation and developed in partnership with NIAID and HVTN.

10VIR-1949
CategoryInvestigational HPV therapeutic vaccine
Description

Investigational therapeutic vaccine candidate leveraging Vir's T-cell-based viral vector platform to elicit specific T-cell responses against HPV for the treatment of pre-cancerous HPV lesions.

Scale indicator12 records

Each record includes

Type, Value, Description, Source

Partnership13 partners
Strategic tierFlagshipTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2025-12-01
Description

Exclusive licensing agreement granting Norgine rights to commercialize the tobevibart + elebsiran combination for chronic hepatitis delta in Europe, Australia, and New Zealand. Norgine paid €55M upfront plus potential milestones and royalties. Generated $64.1M in revenue recognized in Q4 2025.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2025-10-01
Description

Strategic collaboration for the development and commercialization of VIR-5500 (PRO-XTEN masked PSMA-targeted T-cell engager) for metastatic castration-resistant prostate cancer (mCRPC) in the United States. Deal includes $335M in upfront and near-term payments plus a $75M equity investment, with up to $1.7B in total potential value including development, regulatory, and commercial milestones plus tiered royalties. Vir retains certain rights outside the US.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2020-04-01
Description

Strategic collaboration for the research, development, and commercialization of monoclonal antibodies for coronaviruses. Includes sotrovimab (Xevudy), a SARS-CoV-2 neutralizing antibody that received emergency use authorization. GSK led global commercialization (outside of China).

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2018-06-01
Description

Strategic collaboration to develop and commercialize siRNA (small interfering RNA) therapeutics for infectious diseases, including hepatitis B and hepatitis delta. Elebsiran (VIR-2218) is a key product of this collaboration targeting hepatitis B surface antigen.

Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2017-01-01
Description

License agreement with Amunix Pharmaceuticals (acquired by Sanofi in 2022) granting Vir rights to the PRO-XTEN® protein masking platform for development of masked T-cell engagers and other therapeutics in oncology and infectious disease.

Strategic tierMajorTypeStrategic or Co-development Partner
Description

Co-development partner for tobevibart and elebsiran. Brii Biosciences retains rights to develop and commercialize these products in Greater China. The two companies are engaged in arbitration regarding the partnership agreement.

Strategic tierCoreTypeOEM/ Whitelabel/ Licensing Partner
Description

License to Xencor's Xtend™ antibody half-life extension technology, which is incorporated into tobevibart to extend its in vivo half-life and reduce dosing frequency.

8National Institute of Allergy and Infectious Diseases (NIAID)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Government research partner supporting HIV vaccine development, including the VIR-1388 cytomegalovirus vector-based HIV T-cell vaccine candidate.

Strategic tierCoreTypeImplementation/ SI/ Consulting Partner
Description

Clinical trial network collaboration supporting the conduct of HIV vaccine clinical trials, including those for VIR-1388. HVTN is part of the NIAID-supported clinical trial infrastructure.

Strategic tierCoreTypeTechnology or Integration
Description

Wholly-owned subsidiary of Vir Biotechnology based in Bellinzona, Switzerland, focused on antibody discovery and immunology research. Integral to Vir's antibody platform and originally acquired to anchor the company's European research operations.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Research collaboration supporting antibody discovery and immunology research leveraging IRB Bellinzona's expertise.

12Oregon Health & Science University (OHSU)
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Research collaboration for infectious disease research, including HIV and other viral pathogens.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Scientific collaboration providing access to European scientific expertise and research capabilities in immunology and infectious disease.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Arbutus Biopharma is a clinical-stage biopharmaceutical company developing RNAi therapeutics for chronic hepatitis B and hepatitis delta. It is the most direct competitor to Vir's tobevibart + elebsiran combination, targeting the same HDV patient population with siRNA-based approaches.

TypeDirect peer
Description

Alnylam Pharmaceuticals is the siRNA platform company and Vir's own partner on elebsiran. It is a direct comparable in the siRNA/RNAi therapeutics space, with a commercial-stage franchise (Onpattro, Givlaari, Oxlumo) and pipeline spanning rare diseases and infectious diseases including hepatitis.

TypeBroad incumbent
Description

Regeneron is a large biopharmaceutical company with the VelocImmune antibody discovery platform, analogous to Vir's dAIsY/survivor-repertoire approach. It has commercial monoclonal antibodies (Dupixent, Inmazeb/Ebola) and a deep infectious disease and oncology pipeline, making it a direct platform comparable.

TypeBroad incumbent
Description

Moderna is a major mRNA-based infectious disease and oncology company. It overlaps with Vir in COVID-19 antibody/vaccine development and broader infectious disease focus, and represents a comparable public biopharmaceutical platform with similar scope of pipeline.

TypeEmerging player
Description

Viridian Therapeutics is a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for serious diseases, with a focus on Fc engineering. Its antibody engineering approach and clinical-stage positioning make it a comparable emerging antibody platform peer.

TypeDirect peer
Description

AbCellera is an antibody discovery platform company partnering with Vir for high-throughput single-cell antibody screening. It is a direct technology and platform comparable, with its own pipeline of clinical-stage antibody candidates across infectious disease and oncology.

TypeBroad incumbent
Description

Gilead is a large biopharmaceutical company with deep expertise in antiviral therapeutics (HIV, hepatitis B, hepatitis C) and a growing oncology franchise. Its infectious disease franchise and antibody/vaccine approaches overlap directly with Vir's pipeline focus, and a former Gilead R&D leader (Norbert Bischofberger) sits on Vir's board.

TypeBroad incumbent
Description

Amgen is the pioneer of T-cell engager therapeutics via the BiTE platform (Blincyto) and a major antibody developer. It is a broad incumbent comparable in the T-cell engager space that Vir's PRO-XTEN platform is designed to differentiate from.

TypeBroad incumbent
Description

Astellas is Vir's strategic partner for VIR-5500 and a major Japanese oncology biopharmaceutical company. It is comparable as a large incumbent in the mCRPC and T-cell engager spaces, with established commercial infrastructure that Vir is leveraging.

TypeBroad incumbent
Description

Roche/Genentech is a global biopharmaceutical leader in oncology and infectious disease antibodies. It is a broad incumbent peer with overlapping T-cell engager development and antibody platform technology.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability2 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature9 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles15 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance7 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds12 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors13 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A3 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Vir Biotechnology

Biopharmaceuticalsvir.bio

Vir Biotechnology is a clinical-stage biopharmaceutical company that develops antibody-based immunotherapies for infectious diseases and cancer, with a Phase 3 hepatitis delta program and three oncology T-cell engager candidates. The San Francisco-based, NASDAQ-listed firm (VIR) partners with Astellas, Norgine, and others to commercialize its pipeline.

What Vir Biotechnology does

Vir Biotechnology is a clinical-stage biopharmaceutical company headquartered in San Francisco, California, with antibody discovery operations through its wholly-owned subsidiary Humabs BioMed SA in Bellinzona, Switzerland. Founded in 2016 and listed on NASDAQ under the ticker VIR, the company develops therapeutics that engage the immune system to treat and prevent serious infectious diseases and cancer, supported by two core technology platforms: a proprietary antibody and T-cell engager discovery platform that combines natural antibody repertoires from recovered patients with the proprietary dAIsY AI engine for candidate optimization, and the PRO-XTEN protease-releasable masking platform (licensed from Amunix Pharmaceuticals, a Sanofi company) that enables tumor-selective activation of potent T-cell engagers.

The company's most advanced clinical program is the tobevibart + elebsiran combination for chronic hepatitis delta virus (HDV) infection, currently in the Phase 3 SOLSTICE/ECLIPSE registrational trial with FDA Breakthrough Therapy, FDA Fast Track, EMA PRIME, and EU Orphan Drug designations. The oncology pipeline consists of three PRO-XTEN-masked T-cell engagers — VIR-5500 (PSMA, partnered globally with Astellas Pharma), VIR-5818 (HER2), and VIR-5525 (EGFR) — all in Phase 1 development. Earlier-stage programs include the CMV-vector-based HIV T-cell vaccine VIR-1388, next-generation COVID-19 antibody VIR-7229, influenza antibody VIR-2981, and HPV therapeutic vaccine VIR-1949. Vir has a historical track record of FDA-approved antibodies including ansuvimab-zykl for Ebola (2020) and sotrovimab for COVID-19 (with GSK).

Vir's business model is partnership-driven: it monetizes assets through licensing and collaboration agreements rather than direct sales, generating revenue from upfront payments, milestones, royalties, and non-dilutive government and foundation grants (BARDA, Bill & Melinda Gates Foundation). Recent major transactions include the global Astellas collaboration for VIR-5500 (up to $1.7B total value, $335M upfront/near-term plus $75M equity) and the Norgine exclusive license for hepatitis delta in Europe, Australia, and New Zealand (€55M upfront plus up to €495M in milestones). The company retains US commercial rights for hepatitis delta and is building internal commercial capabilities for direct US launch, while the Brii Biosciences partnership covers Greater China. As of Q1 2026, Vir held $809.3M in cash and investments, reported a $125.7M quarterly net loss, and was led by CEO Marianne De Backer (appointed April 2023).

Vir Biotechnology firmographics

Firmographics
Name
Vir Biotechnology
Legal name
Vir Biotechnology, Inc.
Website
https://vir.bio
Company type
Public
Founded year
2016
Operating status
Operating
Headcount range
251–500 employees
Short description
Vir Biotechnology is a clinical-stage biopharmaceutical company that develops antibody-based immunotherapies for infectious diseases and cancer, with a Phase 3 hepatitis delta program and three oncology T-cell engager candidates. The San Francisco-based, NASDAQ-listed firm (VIR) partners with Astellas, Norgine, and others to commercialize its pipeline.
Ownership category
akta.pro rank

Vir Biotechnology industry classification

Industry
Product category
Biopharmaceuticals
NAICS
Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAADAA
mRNA Therapeutics (vaccines, protein replacement, immuno-oncology)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAAEAD
Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAAABAL
Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)

Keywords

  • Monoclonal antibody therapeutics
  • Infectious disease treatments
  • Oncology biologics
  • T-cell engager therapies
  • Clinical-stage biopharmaceuticals

Where Vir Biotechnology is headquartered

Location

Headquarters

HQ city
San Francisco
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Vir Biotechnology business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Collaboration and License Revenue: Upfront payments, milestone payments, and equity investments from strategic partners. Includes $335M in upfront and near-term payments from Astellas (plus $75M equity investment) for the VIR-5500 license, and €55M upfront from Norgine for the chronic hepatitis delta license in Europe. Q4 2025 recognized $64.1M in revenue from the Norgine transaction.
  2. Government and Foundation Grants: Non-dilutive funding from agencies and foundations for specific R&D programs. Includes BARDA funding for COVID-19 and pandemic preparedness, and Bill & Melinda Gates Foundation grants for HIV vaccine and HIV cure research.
  3. Equity Financing (Public Offerings): Capital raised through public stock offerings to fund clinical development. Recently completed a $172.5M public offering of 20,294,117 shares at $8.50 per share.
  4. Royalty and Milestone Payments (Future): Future revenue from licensed products including tiered royalties and development/commercial milestones. The Astellas deal includes up to $1.7B in total potential value including milestones and royalties on VIR-5500 sales in the US.

Pricing tiers

ModelBillingPrice
OtherPay-as-you-goPublic equity offering — February 2026
OtherMulti-year contractNorgine licensing transaction (chronic hepatitis delta, Europe)
OtherMulti-year contractAstellas strategic collaboration (VIR-5500, US)

Go-to-market motion3 records

Distribution channels3 records

Marketing channels6 records

Vir Biotechnology product offering

Product offering

Core offering

Vir Biotechnology is a clinical-stage biopharmaceutical company that develops antibody-based immunotherapies for infectious diseases and cancer. Its pipeline includes monoclonal antibodies (e.g., tobevibart), siRNA therapeutics (e.g., elebsiran), and PRO-XTEN-masked T-cell engagers, with its lead program (tobevibart + elebsiran) in Phase 3 for chronic hepatitis delta. The company commercializes through strategic partnerships with Astellas (prostate cancer), Norgine (hepatitis delta in Europe), GSK (sotrovimab for COVID-19), and Alnylam (siRNA), supported by its proprietary dAIsY AI antibody discovery engine and the licensed PRO-XTEN masking platform.

Product overview

Vir Biotechnology operates a platform-plus-program portfolio built on two core technology platforms (the Antibody and T-cell Engager Discovery and Engineering Platform and the PRO-XTEN® protease-releasable masking platform) that together support a clinical pipeline spanning infectious diseases and oncology. The clinical portfolio includes the lead registrational hepatitis delta program (tobevibart + elebsiran), three PRO-XTEN-masked T-cell engagers (VIR-5818 targeting HER2, VIR-5500 targeting PSMA co-developed with Astellas, and VIR-5525 targeting EGFR), marketed antibodies (sotrovimab for COVID-19, ansuvimab-zykl for Ebola), and earlier-stage candidates in HIV (VIR-1388), HPV (VIR-1949), influenza (VIR-2981), and next-generation COVID-19 (VIR-7229), supported by the proprietary dAIsY AI engine and collaborations with partners including Astellas, Norgine, Brii Biosciences, and the Bill & Melinda Gates Foundation.

Differentiator

Problem solved

Functional benefit

Products and services

  • Tobevibart + Elebsiran combination Investigational combination of a neutralizing monoclonal antibody (tobevibart, incorporating Xencor's Xtend Fc technology) and an siRNA (elebsiran) for the treatment of chronic hepatitis delta virus (HDV) infection, currently in Phase 3 development for patients with chronic HDV, a severe form of viral hepatitis with no approved therapies in the US.
  • VIR-5500 Investigational PSMA-targeting PRO-XTEN dual-masked T-cell engager for metastatic castration-resistant prostate cancer (mCRPC), evaluated alone and in combination with androgen receptor pathway inhibitors; partnered globally with Astellas Pharma in a deal worth up to $1.7 billion.
  • VIR-5818 Investigational HER2-targeting PRO-XTEN dual-masked T-cell engager being evaluated alone or in combination with pembrolizumab for HER2-expressing solid tumors; currently in Phase 1 clinical development.
  • VIR-5525 Investigational EGFR-targeting PRO-XTEN dual-masked T-cell engager being evaluated alone or in combination with pembrolizumab for EGFR-expressing solid tumors; currently in Phase 1 clinical development.
  • Sotrovimab Investigational monoclonal antibody treatment for COVID-19, identified by Vir's antibody platform and engineered for immune engagement; delivered during the pandemic in partnership with GlaxoSmithKline.
  • Ansuvimab-zykl FDA-approved (2020) monoclonal antibody treatment for Ebola virus disease (Zaire ebolavirus), derived from Vir Biotechnology's antibody discovery platform.
  • VIR-7229 Next-generation COVID-19 monoclonal antibody candidate optimized via AI engineering for increased potency, breadth, and resistance to viral escape; developed with BARDA support for high-risk populations including immunocompromised individuals.
  • VIR-2981 Investigational monoclonal antibody candidate with in vitro potent activity against all major strains of influenza A and B viruses, targeting high-risk populations including the elderly and immunocompromised.
  • VIR-1388 Investigational HIV T-cell vaccine based on a human cytomegalovirus (HCMV) vector platform designed to elicit CD8+ T-cell immune responses against HIV, supported by the Bill & Melinda Gates Foundation and developed in partnership with NIAID and HVTN.
  • VIR-1949 Investigational therapeutic vaccine candidate leveraging Vir's T-cell-based viral vector platform to elicit specific T-cell responses against HPV for the treatment of pre-cancerous HPV lesions.

Quantifiable outcome

  • Phase 3 SOLSTICE trial readout for tobevibart + elebsiran combination in chronic hepatitis delta expected to support regulatory approval and commercial launch in US and Europe
  • +2 more outcomes

Companies that use Vir Biotechnology

Customer profile

Segments5 records

Ideal customer profiles1 record

Vir Biotechnology technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature9 records

Vir Biotechnology partnerships and signals

Strategic signal

Partnerships

13 partnerships are on record, tiered flagship, major, core and minor.

  • NorgineflagshipOEM/ Whitelabel/ Licensing Partner · 1 December 2025Exclusive licensing agreement granting Norgine rights to commercialize the tobevibart + elebsiran combination for chronic hepatitis delta in Europe, Australia, and New Zealand. Norgine paid €55M upfront plus potential milestones and royalties. Generated $64.1M in revenue recognized in Q4 2025.
  • Astellas PharmaflagshipStrategic or Co-development Partner · 1 October 2025Strategic collaboration for the development and commercialization of VIR-5500 (PRO-XTEN masked PSMA-targeted T-cell engager) for metastatic castration-resistant prostate cancer (mCRPC) in the United States. Deal includes $335M in upfront and near-term payments plus a $75M equity investment, with up to $1.7B in total potential value including development, regulatory, and commercial milestones plus tiered royalties. Vir retains certain rights outside the US.
  • GlaxoSmithKline (GSK)majorStrategic or Co-development Partner · 1 April 2020Strategic collaboration for the research, development, and commercialization of monoclonal antibodies for coronaviruses. Includes sotrovimab (Xevudy), a SARS-CoV-2 neutralizing antibody that received emergency use authorization. GSK led global commercialization (outside of China).
  • Alnylam PharmaceuticalsmajorStrategic or Co-development Partner · 1 June 2018Strategic collaboration to develop and commercialize siRNA (small interfering RNA) therapeutics for infectious diseases, including hepatitis B and hepatitis delta. Elebsiran (VIR-2218) is a key product of this collaboration targeting hepatitis B surface antigen.
  • Sanofi (Amunix Pharmaceuticals)coreOEM/ Whitelabel/ Licensing Partner · 1 January 2017License agreement with Amunix Pharmaceuticals (acquired by Sanofi in 2022) granting Vir rights to the PRO-XTEN® protein masking platform for development of masked T-cell engagers and other therapeutics in oncology and infectious disease.
  • Brii BiosciencesmajorStrategic or Co-development PartnerCo-development partner for tobevibart and elebsiran. Brii Biosciences retains rights to develop and commercialize these products in Greater China. The two companies are engaged in arbitration regarding the partnership agreement.
  • XencorcoreOEM/ Whitelabel/ Licensing PartnerLicense to Xencor's Xtend™ antibody half-life extension technology, which is incorporated into tobevibart to extend its in vivo half-life and reduce dosing frequency.
  • National Institute of Allergy and Infectious Diseases (NIAID)coreStrategic or Co-development PartnerGovernment research partner supporting HIV vaccine development, including the VIR-1388 cytomegalovirus vector-based HIV T-cell vaccine candidate.
  • HIV Vaccine Trials Network (HVTN)coreImplementation/ SI/ Consulting PartnerClinical trial network collaboration supporting the conduct of HIV vaccine clinical trials, including those for VIR-1388. HVTN is part of the NIAID-supported clinical trial infrastructure.
  • Humabs BioMed SAcoreTechnology or IntegrationWholly-owned subsidiary of Vir Biotechnology based in Bellinzona, Switzerland, focused on antibody discovery and immunology research. Integral to Vir's antibody platform and originally acquired to anchor the company's European research operations.
  • Institute for Research in Biomedicine (IRB Barcelona)minorStrategic or Co-development PartnerResearch collaboration supporting antibody discovery and immunology research leveraging IRB Bellinzona's expertise.
  • Oregon Health & Science University (OHSU)minorStrategic or Co-development PartnerResearch collaboration for infectious disease research, including HIV and other viral pathogens.
  • VIB-Ghent UniversityminorStrategic or Co-development PartnerScientific collaboration providing access to European scientific expertise and research capabilities in immunology and infectious disease.

Scale indicators12 records

Recent moves6 records

Expansion highlights6 records

Vir Biotechnology competitors and assessment

Company assessment

Direct peers

  • Arbutus Biopharma: Arbutus Biopharma is a clinical-stage biopharmaceutical company developing RNAi therapeutics for chronic hepatitis B and hepatitis delta. It is the most direct competitor to Vir's tobevibart + elebsiran combination, targeting the same HDV patient population with siRNA-based approaches.
  • Alnylam Pharmaceuticals: Alnylam Pharmaceuticals is the siRNA platform company and Vir's own partner on elebsiran. It is a direct comparable in the siRNA/RNAi therapeutics space, with a commercial-stage franchise (Onpattro, Givlaari, Oxlumo) and pipeline spanning rare diseases and infectious diseases including hepatitis.
  • AbCellera Biologics: AbCellera is an antibody discovery platform company partnering with Vir for high-throughput single-cell antibody screening. It is a direct technology and platform comparable, with its own pipeline of clinical-stage antibody candidates across infectious disease and oncology.

Broad incumbents

  • Regeneron Pharmaceuticals: Regeneron is a large biopharmaceutical company with the VelocImmune antibody discovery platform, analogous to Vir's dAIsY/survivor-repertoire approach. It has commercial monoclonal antibodies (Dupixent, Inmazeb/Ebola) and a deep infectious disease and oncology pipeline, making it a direct platform comparable.
  • Moderna: Moderna is a major mRNA-based infectious disease and oncology company. It overlaps with Vir in COVID-19 antibody/vaccine development and broader infectious disease focus, and represents a comparable public biopharmaceutical platform with similar scope of pipeline.
  • Gilead Sciences: Gilead is a large biopharmaceutical company with deep expertise in antiviral therapeutics (HIV, hepatitis B, hepatitis C) and a growing oncology franchise. Its infectious disease franchise and antibody/vaccine approaches overlap directly with Vir's pipeline focus, and a former Gilead R&D leader (Norbert Bischofberger) sits on Vir's board.
  • Amgen: Amgen is the pioneer of T-cell engager therapeutics via the BiTE platform (Blincyto) and a major antibody developer. It is a broad incumbent comparable in the T-cell engager space that Vir's PRO-XTEN platform is designed to differentiate from.
  • Astellas Pharma: Astellas is Vir's strategic partner for VIR-5500 and a major Japanese oncology biopharmaceutical company. It is comparable as a large incumbent in the mCRPC and T-cell engager spaces, with established commercial infrastructure that Vir is leveraging.
  • Roche / Genentech: Roche/Genentech is a global biopharmaceutical leader in oncology and infectious disease antibodies. It is a broad incumbent peer with overlapping T-cell engager development and antibody platform technology.

Emerging players

  • Viridian Therapeutics: Viridian Therapeutics is a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for serious diseases, with a focus on Fc engineering. Its antibody engineering approach and clinical-stage positioning make it a comparable emerging antibody platform peer.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Vir Biotechnology social profiles

Digital presence

Vir Biotechnology compliance and trust

Trust signal

Compliance7 records

Vir Biotechnology financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Vir Biotechnology leadership team

Management profile

Number of profiles

Profiles15 records

Vir Biotechnology subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Vir Biotechnology funding detail

Funding detail

Funding overview

Funding rounds12 records

Investors13 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Vir Biotechnology M&A and investment

M&A and investment

M&A3 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Vir Biotechnology

What does Vir Biotechnology do?

Vir Biotechnology is a clinical-stage biopharmaceutical company that develops antibody-based immunotherapies for infectious diseases and cancer. Its pipeline includes monoclonal antibodies (e.g., tobevibart), siRNA therapeutics (e.g., elebsiran), and PRO-XTEN-masked T-cell engagers, with its lead program (tobevibart + elebsiran) in Phase 3 for chronic hepatitis delta. The company commercializes through strategic partnerships with Astellas (prostate cancer), Norgine (hepatitis delta in Europe), GSK (sotrovimab for COVID-19), and Alnylam (siRNA), supported by its proprietary dAIsY AI antibody discovery engine and the licensed PRO-XTEN masking platform.

Is Vir Biotechnology a public or private company?

Vir Biotechnology is a public company. It is classified as public and is currently operating.

When was Vir Biotechnology founded?

Vir Biotechnology was founded in 2016. It employs 251 to 500 people.

Where is Vir Biotechnology based?

Vir Biotechnology is headquartered in San Francisco, United States, in the North America region.

How does Vir Biotechnology make money?

Four revenue lines are on record. Collaboration and License Revenue is the primary driver. The others are government and Foundation Grants, equity Financing (Public Offerings) and royalty and Milestone Payments (Future).

Who are Vir Biotechnology's main competitors?

Direct peers on record are Arbutus Biopharma, Alnylam Pharmaceuticals and AbCellera Biologics. Broad incumbents are Regeneron Pharmaceuticals, Moderna, Gilead Sciences, Amgen, Astellas Pharma and Roche / Genentech. Viridian Therapeutics is listed as an emerging player.

Does Vir Biotechnology have an API?

No public API is recorded for Vir Biotechnology.

What industry is Vir Biotechnology in?

Vir Biotechnology's product category is Biopharmaceuticals. Its primary akta.pro industry code is HLAAADAA, mRNA Therapeutics (vaccines, protein replacement, immuno-oncology), with a secondary code of HLAAAEAD, Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
The future of tradingVir Biotechnology grants Chief Accounting Officer Brent Sabatini 50,000 restricted stock unitsVir Biotechnology awarded Chief Accounting Officer Brent Sabatini 50,000 restricted stock units on November 15, 2026. The grant was published via EDGAR on November 16, 2026.TradingViewVir Biotechnology Prices $150 Million Stock Offering at $10 Per ShareVir Biotechnology entered an underwriting agreement with Leerink Partners, Morgan Stanley, and Evercore for a 15 million share offering at $10 per share, raising $150 million in gross proceeds. The offering is expected to close on November 16, 2026, with net proceeds of approximately $140.4 million, or $161.5 million if the underwriters exercise their 30-day option to buy up to 2.25 million additional shares.YahooVir Biotechnology Shares Drop as Biotech Firm Moves Ahead With Stock SaleVir Biotechnology shares fell 10% early Friday after the company set terms for a public stock sale. It is selling 15 million shares at $10 each, with a base offering of $150 million and an option for underwriters to buy up to 2.25 million more. The transaction is expected to close on Nov. 16, 2026.TradingViewVir Biotechnology Shares Drop as Biotech Firm Moves Ahead With Stock SaleVir Biotechnology shares fell 10% early Friday after the company set terms for a public stock sale. The firm is selling 15 million shares at $10 each, with a base offering of $150 million and an option for underwriters to buy up to 2.25 million more. The transaction is expected to close on Nov. 16, 2026.YahooVir Biotechnology stock tumbles on $150M share offeringVir Biotechnology shares fell 15% in premarket trade after announcing a $150 million public stock offering priced at $10 per share. The company will sell 15 million shares, with gross proceeds expected to reach $150 million before deducting underwriting discounts and commissions. The offering is expected to close on November 16, 2026.Investing.comVir Biotechnology stock tumbles on $150M share offeringVir Biotechnology shares fell 15% in premarket trade after announcing a $150 million public stock offering priced at $10 per share. The company will sell 15 million shares, with underwriters granted a 30-day option to buy up to 2.25 million more. The offering is expected to close on November 16, 2026.Investing.comWhy is Vir Biotechnology stock tumbling today?Vir Biotechnology's stock fell 16.2% in pre-open trading after it priced an underwritten public offering of 15 million shares at $10.00 per share, targeting about $150 million in gross proceeds. The offering was priced roughly 17.5% below the prior closing price of $12.12, and closing is expected on November 16, 2026.MarketWatchVir Biotechnology Shares Fall After $150 Million Stock Offering Is PricedVir Biotechnology shares fell 13% to $10.50 after its $150 million underwritten public offering was priced. The company will sell 15 million shares at $10 each, with gross proceeds of about $150 million before costs. The offering is expected to close Monday.Seeking AlphaBiggest stock movers Friday: CBRS, FLO, and moreFriday's biggest stock movers included Cerebras Systems, Nu Holdings, and Vir Biotechnology, with Cerebras and Nu gaining and Vir and Flowers Foods losing. Cerebras beat Q3 revenue expectations and raised its FY2026 outlook, while Flowers Foods missed earnings and cut its guidance.TradingViewVir Biotechnology dips 15%, prices $150M equity raise $10 per shareVir Biotechnology priced a 15M-share public offering at $10 per share, generating expected gross proceeds of $150M. The company granted underwriters a 30-day option to buy up to 2.25M additional shares, and the offering is expected to close on November 16. Shares fell 15% in premarket trading Friday.